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The role of perlecan and endorepellin in the control of tumor 
angiogenesis and endothelial cell autophagy
Stephen Douglass, Atul Goyal, and Renato V. Iozzo
Department of Pathology, Anatomy and Cell Biology and the Cancer Cell Biology and Signalling 
Program, Kimmel Cancer Centre, Sidney Kimmel Medical College at Thomas Jefferson 
University, Philadelphia, PA 19107, USA
Abstract
During tumor growth and angiogenesis there is a dynamic remodelling of tissue architecture often 
accompanied by the release of extracellular matrix constituents full of biological activity. One of 
the key constituents of the tumor microenvironment is the large heparan sulfate proteoglycan 
perlecan. This proteoglycan, strategically located at cell surfaces and within basement membranes, 
is a well-defined pro-angiogenic molecule when intact. However, when partially processed by 
proteases released during cancer remodelling and invasion, the C-terminal fragment of perlecan, 
known as endorepellin, has opposite effects than its parent molecule. Endorepellin is a potent 
inhibitor of angiogenesis by exerting a dual receptor antagonism by simultaneously engaging 
VEGFR2 and α2β1 integrin. Signaling through the α2β1 integrin leads to actin disassembly and 
block of endothelial cell migration, necessary for capillary morphogenesis. Signaling through the 
VEGFR2 induces dephosphorylation of the receptor via activation of SHP-1 and suppression of 
downstream proangiogenic effectors, especially attenuating VEGFA expression. A novel and 
emerging role of endorepellin is its ability to evoke autophagy by activating Peg3 and various 
canonical autophagic markers. This effect is specific for endothelial cells as these are the primary 
cells expressing both VEGFR2 and α2β1 integrin. Thus, an endogenous fragment of a ubiquitous 
proteoglycan can regulate both angiogenesis and autophagy through a dual receptor antagonism. 
The biological properties of this natural endogenous protein place endorepellin as a potential 
therapeutic agent against cancer or diseases where angiogenesis is prominent.
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Introduction
The extracellular matrix (ECM) is a biological structure that is found in all multi-cellular 
organisms. It provides physical scaffolding through adhesive interactions between adjacent 
cells, and also biochemical support by mediating a number of signalling processes through 
the direct interaction with various growth factor receptors located on ECM-associated cells 
(1-3). The ECM is the primary feature that dictates organismal architecture and many of its 
biological roles are maintained within various animal lineages. These roles are 
predominantly cell adhesion and cell-to-cell communication. However, due to an 
independent evolution rate between multi-cellular lineages, ECM constituents often differ 
among organisms and animals of differing species (4) and have the ability to utilize a wide 
variety of biological roles, which they use to fit the biological task they require (5). A major 
class of molecules found within the ECM is proteoglycans, an expanding family of gene 
products that now encompass 43 distinct genes belonging to four families (6). Deregulated 
expression of many proteoglycans has been closely linked to the onset of a number of 
pathologies including wound healing, tumor growth, fibrosis and abnormal angiogenesis (7). 
This emphasizes the importance of a balanced and controlled expression of these 
biologically active proteoglycans. This minireview will focus on the roles of the 
proteoglycan perlecan and its C-terminal fragment, endorepellin, in cancer, angiogenesis and 
autophagy.
Perlecan genetics
Heparan sulfate proteoglycans (HSPGs) are a special class of proteoglycans, which govern 
crucial events in embryonic development, inflammation, wound repair and cancer. Perlecan, 
also known as HSPG2, is one of the largest proteoglycans found in the body (8,9). It was 
originally isolated from mouse basement membrane (10) and given its eponym from its 
appearance of a “beads on a string” on rotary shadow electron microscopy. It was later 
discovered that the cell-surface HSPG of human colon carcinoma cells was essentially the 
same as perlecan (11-13). It has a protein core of ~470 kDa and contains three HS chains 
located at the N-terminus (Figure 1A), each weighing approximately 30 kDa. Perlecan is 
encoded by the HSPG2 gene located on the short arm (p) of chromosome 1, specifically 
1p36 (13). This large gene covers >120 kb of continuous DNA and contains 97 protein-
encoding exons (14). The HSPG2 gene has a complex organization at the promoter level 
(15,16), and is an early response gene that is transcriptionally inhibited by interferon γ (17) 
and induced by TGFβ (18) and phorbol ester (19). Its promoter complexity is further 
enhanced by the potential generation of alternatively-spliced mRNA variants reported to 
occur in mast cells (20,21).
The expression profile of perlecan during development follows a non-random and defined 
pattern. Within early phases, perlecan can be found within the endothelial cells of the 
cardiac tissue such as the heart and blood vessels, followed later by being expressed in the 
liver, kidney and spleen (22). Lack of perlecan in developing Hspg2−/− mouse embryo leads 
to severe brain, heart, and skeletal dysplasia responsible for death between embryonic stage 
E10.5 and birth, primarily because of blood leakage into the pericardial cavity (23,24). 
Importantly, this is around the stage of development when perlecan expression is induced. 
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Moreover, Hspg2−/− mice develop severe skeletal dysplasia characterized by shortened 
bones and craniofacial abnormalities, and die shortly after birth of respiratory failure due to 
the cartilage defects of the rib cage (23,24).
Mutations in the human perlecan gene can cause at least two autosomal recessive skeletal 
disorders, the dyssegmental dysplasia Silverman-Handmaker type (DDSH) (25,26), and the 
Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia (SJS) (27-29). 
DDSH new-borns display massive skeletal abnormalities and die shortly after birth. SJS is 
represented by a range of mutations with most patients reaching adulthood exhibiting a 
spectrum of disorders related to the degree of haplo-insufficiency, notably severe muscle 
stiffness (29). In addition to the disorganization of the growth plate and chondro-osseous 
junction of bones caused by the absence of perlecan, there are other distortions in the growth 
of joints including the temporo-mandibular joint, myotonia and electrical disturbances of 
muscle and modifications to the structures of facial bones (30). Moreover, perlecan 
deficiency in hypomorphic mutant mice influences bone formation by enhancing 
osteogenesis and concurrently affects mineralization, leading to increased brittleness at older 
ages (31).
The absence of perlecan affects FGF signalling in the growth plate (23). Hspg2 mutant mice 
with a knock-in mutation Cys1532Tyr, found in human SJS, have a phenotype similar to 
SJS (32). These findings provide robust genetic evidence demonstrating the critical need for 
perlecan expression and also the importance of the protein core in cardiovascular 
development. Recent studies designed to unravel the cause of the leakage into the pericardial 
cavity have shown that basement membranes lacking perlecan deteriorate in the heart with 
accompanying loss of cell–cell attachment in the ventricle and outflow tract (33).
Perlecan protein core and its functions
The protein core of perlecan is composed of five distinct modules which are schematically 
illustrated in Figure 1A. Perlecan regulates several biological processes by interacting with 
growth factor receptors and soluble growth factors through its HS chains or protein core 
(34-36). Perlecan is widely conserved across animals and is one of the few gene products 
that are found in both vascular and avascular tissues (22,37-40). Due to its large size and 
complex structure, perlecan has many roles. Among these are: cell adhesion and invasion 
(41-45), inhibition of smooth muscle cell proliferation (46-48), cardiovascular development 
(24), lipid metabolism (49-51), corneal epithelial structure (52), epidermal and osteophyte 
formation (53,54), cartilage homeostasis (55), endochondral ossification (56), apoptosis 
(57), lens capsule homeostasis (58), and synaptogenesis (59,60). However the most notable 
role is its ability to promote vessel formation (40,61-65) and angiogenesis (9,66-71). This 
occurs through the binding of several pro-angiogenic factors to the HS chains or the protein 
core (61,64,72-75). Moreover, perlecan binds to several growth factors (76-78), including 
progranulin (79), a protein inducing angiogenesis and cancer growth (80,81). Perlecan can 
be processed by MMP7 at the invasive tumor microenvironment, thereby acting as a 
molecular switch to alter prostate carcinoma and favoring cell invasion (45).
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One of the most intriguing functions of perlecan is its involvement in blood vessel formation 
(1,82). The mRNA levels of perlecan are high in endothelial cells of the developing mouse 
embryo (22), and further increase after recruitment of pericytes to the endothelial tubes. 
Perlecan also supports the maintenance of brain and skin subendothelial basement 
membrane and promotes vascular formation and angiogenesis by modulating FGF2 activity 
(83). Hspg2Δ3/Δ3 mice harboring a 45-bp in-frame deletion of Hspg2 exon 3, which removes 
the attachment sites for HS chains in Domain I, are viable but have small eyes and their 
lenses degenerate within 3 weeks of birth (58). Hspg2Δ3/Δ3 mice also possess impaired 
angiogenesis, delayed wound healing and retarded tumor growth (84). Thus, perlecan HS 
chains play an important role in the regulation of wound healing and tumor growth. Perlecan 
knockdown in zebrafish reveals abnormal phenotypes with a pronounced curvature of the 
tail and trunk caused by severe defects in the musculoskeletal system and inhibition of 
angiogenesis (40). Recently, it has been shown that perlecan deficiency promotes 
endothelial cell dysfunction by reducing the expression of endothelial-specific nitric oxide 
synthase (85), thereby controlling vascular relaxation.
The pro-angiogenic activity of perlecan is thought to be achieved primarily through 
interacting with FGF receptors using the three HS chains present in the N-terminal Domain I 
(61). This interaction actively increases cell proliferation, motility, and adhesion (44,61). 
Often, the HS chains of perlecan can be liberated by either partial proteolysis of the protein 
core (86) or by the activity of heparanase (87). The latter enzyme is known to cleave HS 
generating relatively large fragments (88) that are full of HS-binding mitogens and pro-
angiogenic factors (89). Perlecan HS chains are key factors for angiogenesis in an 
experimental animal model of hind-limb ischemia (71). In this animal model, the HS side 
chains in perlecan are important mediators of the angiogenic response to ischemia through a 
mechanism that involves induction of VEGF expression (71). On the other hand, the HS 
chains of perlecan, which are processed by heparanase released by tumor and inflammatory 
cells (90-94), have a profound inhibitory role on smooth muscle cell proliferation in vivo 
(46,47). Thus, there is a fine balance of activator and inhibitor effects at the N-terminus of 
perlecan, further stressing the biological complexity of this macromolecule.
Deregulated expression of perlecan is reported to be instrumental in cancer progression 
(84,95,96). For instance, in some cancers of the ovaries perlecan expression is lost from the 
basement membrane (97). In others, such as melanomas, oral squamous carcinomas and 
hepatocellular carcinomas, perlecan is markedly upregulated (95,98,99). In the latter case, 
knockdown of perlecan in carcinoma cells isolated from various tumor sites reduces cell 
migration and adhesion (98). Moreover, knockdown of perlecan in metastatic prostate 
cancer cells reduces in vivo tumor growth (100). Perlecan is overexpressed in the 
desmoplastic prostate cancer stroma and this is mediated by TNFα-mediated transcriptional 
induction of perlecan (101). Thus, perlecan transcription could be a part of an innate 
response of the tumor stroma to cancer invasion.
Collectively, these findings posit perlecan and its HS chains as key regulators of 
angiogenesis during tumor progression. Because perlecan acts as a pro- and anti-angiogenic 
HSPG, aberrant perlecan levels and/or abnormal processing during cancer invasion could 
have profound effects on tumor progression and metastasis.
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Endorepellin, the C-terminal angiostatic fragment of perlecan
The most notable region of this HSPG is its C-terminal Domain V (Figure 1A), also known 
as endorepellin to signify its anti-endothelial properties (102). Endorepellin is an 85-kDa 
glycoprotein consisting of three laminin-like globular (LG) repeats separated by epidermal 
growth factor (EGF)-like module doublets. The crystal structure of the LG3 domain has 
been recently solved (103). This region is made up of about 200 amino acids and is 
constructed as a 15-stranded anti-parallel β sandwich forming a jellyroll fold, characteristic 
of LG domains (Figure 1B). Notably, Asp4197 located near the N-terminus of LG3, might be 
a potential binding site for the α2β1 integrin, as mutation of this residue LG3 activity (103).
Endorepellin is not produced alone but must be proteolitically cleaved from secreted 
perlecan, and as such endorepellin has its own repertoire of actions. Generation of bioactive 
endorepellin is mediated by the activity of Cathepsin L (104), the same enzyme that is also 
involved in the generation of endostatin. One can envisage a scenario where, during 
remodelling of basement membranes, Cathepsin L can dually affect angiogenesis. In 
contrast, LG3 is highly sensitive to BMP1-Tolloid-like family of MMPs (105). Once 
cleaved, endorepellin is found in similar regions as perlecan, primarily within the basement 
membrane of epithelial-lining organs and along the cardiovascular system (106). Notably 
increased levels of endorepellin have been found in sarcopenia, the age-related loss of 
skeletal muscle mass and function (107). Endorepellin works by binding with high affinity 
to receptors located on endothelial cells and, therefore, influences the cells lining of the 
vessels. The difference in the receptors targeted by LG modules and the actions they 
provoke are critically assessed in the next sections.
Endorepellin signaling
One of the key features of liberated soluble endorepellin is its ability to signal through 
various receptors including integrins and VEGFRs (108). This signaling ability of perlecan/
endorepellin is also extended to its perlecan ortholog in Drosophila named Trol, for terribly 
reduced optical lobes. Trol regulates multiple developmental stages (109) as well as FGF-
signaling output during mesoderm development (110). Signaling through perlecan regulates 
prostate cancer progression through Sonic Hedgehog (111,112). In mammalians, both 
perlecan and endorepellin can bind VEGFR1 and VEGFR2, at sites independent of the 
VEGFA binding site (113). VEGFA is able to bind to either receptor at picomolar 
concentrations; however VEGFA has approximately 5-fold higher binding capacity for 
VEGFR1 (Kd~100 pM) than VEGFR2 (Kd~480 pM) (114). Notably, endorepellin binds with 
a similar affinity to both receptors as VEGFA (114) and this binding capacity is greater than 
the whole glycanated parental proteoglycan. In competition binding assays, highly-purified, 
human recombinant endorepellin cannot be displaced from either VEGFR1 or VEGFR2 by 
molar excesses of recombinant VEGFA (114). This demonstrates that endorepellin binds to 
a discrete region of VEGFR2 ectodomain that doesn’t overlap with the VEGF ligand 
binding site.
Initially, it was demonstrated that endorepellin binds to the α2β1 integrin on endothelial 
cells (115-119) and platelets (117) where it enhances collagen-platelet response. In addition, 
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endorepellin affects the global proteomic profile of endothelial cells (120). It is well 
established that the α2β1 integrin is an important receptor regulating various aspects of 
angiogenesis (121-123), and is required for endorepellin’s biological activity, both in vitro 
and in tumor xenografts (124). However, it is now known that endorepellin binds to both 
VEGFR2 and α2β1 on endothelial cells (114,125). This causes internalization and 
downregulation of both receptors within 10 minutes of binding; a concept referred to as 
“dual receptor antagonism” (114). Importantly, only the LG1/2 domain of endorepellin can 
interact with VEGFR2, whereas, only the LG3 domain is capable to interact with the α2β1 
integrin (125,126). Indeed, cells expressing α2β1 integrin, but lacking VEGFR2, are 
incapable of responding to endorepellin (114). LG1/2 and the LG3 domains are able to elicit 
different responses independently of each other (126). This suggests that cells that lack α2β1 
but do express VEGFR2, may actually be able to respond to endorepellin but specifically 
only to the LG1/2 domain.
The downstream cascades from the dual signalling by endorepellin have been investigated 
using an antibody array capable of probing the phosphorylation status of numerous receptor 
tyrosine kinases (RTKs) (119). True to its angiostatic activity, endorepellin reduces the 
phosphorylation of key receptors involved with angiogenesis including VEGFR1/2, EGFR 
and ROR2 (119). These findings were further validated when the effects of endorepellin 
were hampered following functional blockage of the key endorepellin receptor, α2β1. 
Following up to 30 minutes of endorepellin treatment, the α2 subunit was immune-
precipitated and revealed that Src homology protein phosphatase-1 (SHP-1) was 
functionally linked to the α2 subunit (119). Moreover, following endorepellin treatment, 
SHP-1 phosphorylation also increases, suggesting that SHP-1 is a key downstream target of 
α2β1 following VEGFR2 engagement by soluble endorepellin. Endorepellin also causes 
SHP-1 to actively translocate from the plasma membrane to the nucleus where it is known to 
influence the transcription of early response genes (119). These findings were validated in 
vivo, as endothelial cells isolated from α2β1−/− mice following endorepellin treatment have 
significantly reduced VEGFR2 phosphorylation (119).
Endorepellin signalling is able to influence the activity of two important signalling branches, 
the PI3K/Akt/mTOR and PKC/JNK/AP-1 pathways (Figure 2A), both of which are thought 
to be primarily governed by SHP-1 bioactivity (113). Under normal physiological 
conditions, PLCγ and the adaptor protein Shb are bound to VEGFR2 at Tyr1175. When these 
proteins become phosphorylated they activate the PI3K/Akt/mTOR and PKC/JNK/AP-1 
pathways, respectively (Figure 2A). As well as being known to translocate to the nucleus to 
regulate genes, SHP-1 is able to dephosphorylate VEGFR2 at Tyr1175 , which in turn causes 
the physical dissociation of Shb and PLCγ from VEGFR2, resulting in decreased signalling 
of PI3K/Akt/mTOR and PKC/JNK/AP-1 pathways (113). Normal signalling of VEGFA is 
able to promote the recruitment of PLCγ to VEGFR2. However, treatment with endorepellin 
can inhibit the effects of VEGFA on PLCγ (113). As endorepellin and VEGFA do not 
compete for the same binding region on VEGFR2, this would suggest that endorepellin 
carries a greater signalling potential than VEGFA, likely by allosterically inhibiting the 
receptor or preventing its dimerization. More studies need to be performed to decipher the 
complexity of downstream signalling and its components.
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Anti-angiogenic properties of endorepellin
Due to the high level expression in cardiovascular tissues and vessels, and the ability of 
endorepellin to signal through VEGFR2, angiogenesis is the most widely reported process 
endorepellin is able to influence (113,114,119). Despite being a key region within the pro-
angiogenic parent molecule perlecan, endorepellin is a potent mediator in repressing 
angiogenesis both in vitro (113,114) and in vivo (119).
HIF-1α is a key transcription factor that is commonly upregulated when cells detect reduced 
oxygen content. This, in turn, promotes angiogenesis to replenish hypoxic regions. 
Endorepellin suppresses HIF-1α levels in porcine aortic endothelial cells (PAE) stably 
overexpressing VEGFR2 (113). Importantly, this downregulation is transcriptionally 
regulated as cells transfected with luciferase driven by the human HIF1A promoter have a 
dose- and time-dependent suppression of the promoter activity following endorepellin 
treatment (113). In support of these findings, blocking VEGFR2, via either small molecule 
inhibitor or siRNA, abrogates the effects of endorepellin, demonstrating that this bioactivity 
is mediated through this receptor. Importantly, soluble endorepellin suppresses HIF1A and 
VEGFA mRNA and inhibits the secretion of VEGFA under hypoxic conditions (113).
There is robust in vivo evidence that supports a role for endorepellin as anti-cancer and anti-
tumor angiogenic factor. When mice bearing either squamous cell or Lewis lung 
carcinomas, are systemically treated with human recombinant endorepellin at clinical 
dosages (5 mg/kg), the exogenously administered endorepellin specifically localizes to the 
tumour vascular system and peri-vascular regions where it remains for several days (116). 
This leads to regression of tumour angiogenesis and also induces a more hypoxic tumour 
microenvironment, whilst decreasing the tumour metabolism and the mitotic index (116). 
These findings put forward bold evidence that endorepellin is able to inhibit tumour growth 
through a number of angiogenic-mediated processes, but also that systemic administration of 
endorepellin is able to specifically target the tumor vascular system, thereby providing a 
proof for targeted tumour specificity. In support of these studies in mammals, exogenous 
administration of endorepellin to zebrafish with morpholino-mediated suppression of 
perlecan expression, can rescue the severe vascular phenotype (40). Although this again 
provides evidence to suggest the effects of endorepellin on angiogenesis, it also suggests 
that endorepellin may have potential therapeutic effects on cardiovascular diseases as well 
as cancer.
Pro-autophagic role of endorepellin
We recently discovered that endorepellin acts as a potent inducer of an intracellular 
catabolic process known as autophagy (126). These effects are also regulated through 
interaction with VEGFR2 and α2β1 (Figure 2B) suggesting that these receptors also hold the 
downstream signaling machinery to regulate several pathways outside of angiogenesis (126).
Autophagy is a catabolic lysosomal process that is conserved across all eukaryotes (127). It 
is a highly-controlled process, which can often be described as pro-survival, where a cell 
uses self-eating as an alternate energy source by degrading and recycling cytosolic 
components (128). Autophagy is stimulated during various pathological and physiological 
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states, such as starvation. In cells starved for nutrients or growth factors, autophagy provides 
crucial nutrients and energy that enhance cell survival through the breakdown of cytosolic 
components. Other cellular stresses, including hypoxia, growth factor withdrawal, and ER 
stress, can also induce autophagy, often to enhance cell survival (129-131). The autophagic 
pathway, essential for embryonic development and organogenesis (132,133), can be 
deregulated in several disorders, including metabolic and infectious diseases, 
neurodegenerative disorders, angiogenesis and cancer (134). According to an emerging 
hypothesis, autophagy provides an anti-carcinogenic function in primary cells by 
safeguarding against metabolic stress through the homeostatic turnover of mitochondria and 
the clearance of protein aggregates. In established tumors, autophagy may confer a survival 
advantage on tumor cells that are under metabolic stress, as a result of a high proliferation 
rate and exposure to hypoxia from insufficient vascularization (135). However, there is also 
strong evidence that sustained angiogenesis evoked by angiostatic proteins negatively affect 
tumor angiogenesis and cancer growth (136).
Notably, other secreted ECM products, including decorin, endostatin and kringle 5, have 
been shown to trigger autophagy (137-139). Endorepellin causes the formation of well-
developed, large autophagosomes in HUVEC that are visible using differential interference 
contrast (DIC) microscopy (Figure 3B), that are similar to those generated by canonical 
autophagy-inducing factors such as rapamycin (Figure 3C), and nutrient deprivation (126). 
Importantly, the number of these structures increases in a dose-dependent manner following 
endorepellin treatment (126). Two key markers of autophagy are Beclin1 and LC3 (140). 
Beclin1 is an important binding partner of class III PI3K-Vps34. Under normal conditions 
Vps34 is found located at the plasma membrane; however, when autophagy is initiated, 
Vps34 is mobilized to the phagophores, the initial formation stage of autophagosomes (141). 
LC3 exists in two forms, LC3-I and LC3-II. The latter is the cytosolic form which is 
conjugated to phosphatidylethanolamine and is recruited to the autophagosomal membranes 
(140). The stimulatory effects of endorepellin on these canonical catabolic markers provide 
the strongest evidence of endorepellin-mediated autophagy.
Following treatment with endorepellin, there is a change in the distribution of Vps34 from 
the plasma membrane to the cytoplasm (126). Interestingly, once redistributed, endorepellin 
evokes the movement of Vps34 into large intracytoplasmic vacuoles, which are Beclin 1 and 
LC3-II positive (126). Although the levels of Vps34 do not significantly change, the levels 
of Beclin 1, LC3 and Peg3 are all increased (126). We previously reported (142) that Peg3 is 
required for decorin-mediated induction of autophagy and proposed that Peg3 should be 
regarded as a marker of autophagy. Interestingly, when Peg3 is depleted, the ability of 
endorepellin to increase Beclin 1 and LC3 is totally abrogated, consistent with a primary 
role for Peg3 in the autophagic process (126). Notably, endorepellin causes co-localization 
of Peg3 with both autophagic markers LC3-II and Beclin 1 (126). These data suggest that 
not only may Peg3 be a novel autophagic protein, but it may also be one of the most reliable 
markers as it is responsible for the induction of Beclin1 and LC3.
As described above, endorepellin has three main LG domains exhibiting profound 
differences in the receptors they target and effects they provoke. LG1/2 binds with high 
affinity to VEGFR2, whereas, the LG3 domain binds α2β1 (114). The importance of these 
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three domains is profound in directing whether endorepellin induces autophagy or inhibits 
angiogenesis. LG1/2, independently of LG3, induces the expression of PEG3, BECN1 and 
MAPLC3A genes. In contrast, signalling by LG3 alone actually reduces the levels of all the 
aforementioned genes (126). This demonstrates that only endorepellin domains LG1/2 are 
able to promote autophagy, which is solely dependent on VEGFR2 (Figure 2B). In contrast, 
the LG3 domain signals through α2β1 and works to repress autophagy. Therefore, the ability 
of endorepellin to induce autophagy is based on VEGFR2, while its anti-angiogenic property 
is based upon dual receptor antagonism, involving VEGFR2 and α2β1 integrin.
Since full length endorepellin is able to induce autophagy (126), it would suggest that 
signalling of LG1/2 through VEGFR2 carries a greater signalling potential and can override 
the effects of LG3 and the α2β1 to reduce autophagy. Further evidence of this signalling 
being solely dependent on VEGFR2 is provided when α2β1 is blocked using anti-α2β1 
blocking antibodies. In this setting, there are no changes in the endorepellin-induced 
increases in PEG3, BECN1 or MAPLC3A (126). However, when VEGFR2 is silenced, the 
ability of endorepellin to increase PEG3, BECN1 and MAPLC3A is markedly suppressed 
(126). Thus, endorepellin evokes a catabolic program in endothelial cells and this aberrant 
autophagy could be detrimental to the formation of cancer-associated blood vessels.
Conclusions
Angiogenesis is an imperative aspect of normal human development. However, this process 
is often aberrant in many forms of cancer where the tumors induce the development of a 
florid blood supply in order to support their progressive increase in growth. The 
proteoglycan perlecan and its C-terminal fragment endorepellin best describe the 
fundamental balance required to maintain the angiogenic system. Perlecan proteoglycan is, 
overall, a pro-angiogenic molecule that is expressed in the cardiovascular system during 
development and in the adult life. In contrast, endorepellin which is found in similar regions 
as perlecan, is strongly anti-angiogenic. Perlecan is a large multidomain proteoglycan that 
has major effects in the development of the cardiovascular system from an embryonic stage 
of development, and into adulthood where perlecan is necessary for proper blood vessel 
maintenance. Perlecan-derived endorepellin signals through a dual receptor antagonism by 
modulating the activity of both VEGFR2 and α2β1 integrin, a process that ultimately leads 
to a suppression of powerful pro-angiogenic cues, including HIF-1α and VEGFA. The 
effects of endorepellin have been demonstrated in a number of in vitro and in vivo models 
placing it in the category of a molecule with true therapeutic potential. More importantly, 
exogenous endorepellin specifically targets the tumour vasculature thereby retarding cancer 
growth, metabolism and angiogenesis. Moreover, as endorepellin targets the α2β1 integrin, a 
powerful pro-angiogenic receptor that is overexpressed in actively-proliferating endothelial 
cells, it exerts a profound effect on tumor angiogenesis vis-à-vis normal blood vessels which 
usually express only low levels of this integrin. As more protein-based therapies to treat 
various pathologies start to be utilized in the clinics, a natural endogenous inhibitor of 
angiogenesis and pro-autophagic factor such as endorepellin could be of potential 
advantage. The use of endorepellin would carry very low risk to patients, as it is non-toxic 
and does not target normal vasculature (116).
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Already the potential diagnostic and prognostic values of LG3 domain of endorepellin have 
been utilized, as LG3 has been reported to be a potential clinical biomarker in patients with 
premature rupture of fetal membranes (143), renal failure (144,145), and in vascular 
allograft rejection (146). Endorepellin and LG3 have been detected in the urine of children 
with sleep apnea (147), in the media conditioned by apoptotic endothelial cells (57,148,149), 
and in the secretome of pancreatic and colon carcinoma cells (105,150-152). Notably, 
circulating LG3 levels are reduced in breast cancer patients, suggesting that LG3 might be a 
useful biomarker for cancer progression and invasion (153). Although the discovery of 
endorepellin is still in its early stages, increasing evidence on the potential anti-cancer 
implications this protein can have is progressing. Granted that before endorepellin can be 
considered in the clinics, much more field work is required. The novel approach of targeted 
therapy using an endogenous protein that bares little toxicity, and aims to use the body’s 
own defence to directly curtail tumors nutrients, certainly represents an exciting avenue to 
explore in cancer treatment.
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Nomenclature
ECM extracellular matrix
GAG glycosaminoglycan
HS heparan sulfate
HSPG HS proteoglycan
GAG glycosaminoglycan
VEGF vascular endothelial cell growth factor
VEGFR VEGF receptor
MMP matrix metalloproteinase
EGF epidermal growth factor
LG laminin-like globular domain
SHP1 Src homology protein phosphatase-1
PLCγ phospholipase Cγ
Shb SH2 domain-containing adaptor protein B
PI3K phosphatidyl inositide 3-kinases
mTOR mammalian target of rapamycin
JNK c-Jun N-terminal kinase
PKC protein kinase C
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AP1 activating protein 1
HIF-1α hypoxia-inducible factor 1α
DIC differential interference contrast microscopy
HUVEC human umbilical vein endothelial cell
LC3 microtubule-associated protein 1A/1B-light chain 3
VPS34 class III phosphoinositide kinase
Peg3 paternally expressed gene 3
PAE porcine aortic endothelial cells
DDSH dyssegmental dysplasia Silverman-Handmaker type
SJS Schwartz-Jampel syndrome
RTK receptor tyrosine kinase
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Figure 1. 
Schematic representation of the multimodular perlecan and its C-terminal endorepellin. (A) 
Perlecan is large multidomain proteoglycan consisting of 5 domains. It contains 3 HS chains 
towards the N-terminus. Domain I contains a SEA module. Domain II is made up of four 
LDL repeats and the first IgG. Following this domain, is Domain III which is made up of 3 
LG repeats, each being separated by 3 laminin-like EGF repeats. Domain IV solely contains 
a further 20 IgG repeats. The C-terminal Domain V, termed endorepellin, has a similar 
structure to Domain III as it contains 3 laminin repeats; however, each of these is separated 
by 2 laminin-like EGF repeats. (B) Refined crystal structure of LG3 domain of endorepellin. 
Image was generated using PDB:3SH4 and presented using PyMol software. LG3 is 
constructed as a 15-stranded anti-parallel β sandwich forming a jellyroll fold characteristic 
of LG domains. The right image represents a 90° rotation along the y axis. This region is 
known to interact with α2β1 integrin located on endothelial cells. The two α helixes are 
illustrated in red, the 12 β sheets are yellow and the loops are green. Of particular note, 
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Asp4197 is highlighted in magenta (circled) and is found at the N-terminus of the protein. 
This amino acid is suggested to be important in the processing of endorepellin. A mutation 
in this amino acid inhibits endorepellin activity. Thus, this site is hypothesised to be a 
potential binding site for the α2β1 integrin.
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Figure 2. 
Schematic representation of the signalling pathways involved in endorepellin-evoked 
intracellular signalling network. (A) The anti-angiogenic effects of endorepellin. 
Endorepellin signals through VEGFR2 via its LG1/2 domain and α2β1 via LG3. This causes 
phosphorylation of SHP-1, which relocates from the plasma membrane to the α2 subunit of 
the integrin. This subsequently causes dephosphorylation of VEGFR2 at Tyr1175, which 
prevents the Shb and PLCγ from binding to VEGFR2 and therefore prevents the activation 
of PI3K/AKt/mTOR and PKC/JNK/AP-1 pathways. These pathways prevent the 
transcription of HIF1A and VEGFA. (B) The pro-autophagic effects of endorepellin. 
Endorepellin signals through VEGFR2 and α2β1in the same manner as previously 
described. Although the involvement of SHP-1 is not yet elucidated, Tyr1175 is again 
dephosphorylated causing Vps34 to re-locate from the plasma membrane and interact with 
Beclin1 in autophagosomes. Beclin 1 then co-localizes with Peg3 and LC3-II. The signalling 
of endorepellin also results in increased mRNA expression of MAPLC3A, BECN1 and Peg3.
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Figure 3. 
Endorepellin induces autophagy in endothelial cells through an mTOR-dependent pathway. 
Representative images of HUVECs following 6 h treatment with vehicle (A) 200 nM 
endorepellin (B) or 100 nM rapamycin (C) in nutrient-enriched conditions. The images were 
captured with differential interference contrast microscopy and fluorescence to detect the 
nucleus stained in blue by DAPI. Notice the formation of multiple autophagosomes (white 
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arrows) in the cytoplasm of the cells in both endorepellin- and rapamycin-treated endothelial 
cells vis-à-vis vehicle-treated controls.
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